Prurigo Nodularis Treatment Market By Product (Antihistamines, Capsacin Cream, Corticosteroids), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), & Region for 2024-2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Prurigo Nodularis Treatment Market Valuation – 2024-2031

The market for Prurigo Nodularis (PN) treatments is really taking off, and it's easy to see why. More and more people are dealing with this condition, and thankfully, both doctors and patients are becoming more aware of it. Prurigo nodularis, with its relentless itchy bumps, can really mess with someone's quality of life. We've seen a real jump in diagnoses over the past ten years, partly because we're getting better at spotting it. Dermatologists and even general practitioners are more clued-in to the disorder. This increased recognition is powering the market, expected to blow past USD 1.30 Billion in revenue in 2024 and aiming for a valuation of around USD 1.90 Billion by 2031.

The increasing use of telemedicine and digital health platforms makes dermatological consultations and treatments more accessible which contributes to the growing demand for PN therapies. As a result, the PN treatment market is predicted to expand significantly driven by a combination of rising illness prevalence, therapeutic improvements, and improved patient access to healthcare services by enabling the market to grow at a CAGR of 5.30% from 2024 to 2031. 

Prurigo Nodularis Treatment MarketDefinition/ Overview

Prurigo nodularis (PN) is a chronic skin disorder distinguished by very irritating nodules that are frequently caused by persistent scratching and inflammation. Prurigo nodularis treatment focuses on symptom relief, itch management, and addressing underlying causes to enhance the patient’s quality of life. Topical therapies are one of the most common methods for treating PN. Corticosteroids, calcineurin inhibitors, and capsaicin lotions are frequently used to treat inflammation and itching.

Prurigo nodularis (PN) is a persistent skin ailment that causes itchy nodules and has a major influence on a patient’s quality of life. Prurigo nodularis is treated using a variety of techniques focused on symptom management, itch relief, and skin lesion improvement. Topical therapies are one of the most common applications for PN therapy. These include corticosteroids, calcineurin inhibitors, and capsaicin creams.

The future of PN management will most likely involve an integrated approach that combines pharmacological and non-pharmacological techniques. As more is learned about the psychological impact of PN, comprehensive treatment strategies that include behavioral therapy, stress management, and lifestyle changes are becoming more widely accepted.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Increasing Demand for Capsaicin Cream Influence the Product Segment?

So, it looks like more and more people are using capsaicin cream to deal with prurigo nodularis, especially when it comes to choosing a treatment. Why? Well, capsaicin, the stuff that makes chili peppers hot, seems to help with that awful itching PN causes. And the number of people dealing with prurigo nodularis is definitely on the rise, which is fueling the demand. In fact, a study in the Journal of the American Academy of Dermatology says that in the US, about 72 out of every 100,000 people have PN. That's roughly 230,000 folks just in the States! The National Eczema Association even notes that PN affects about one in every 4,000 people, showing just how common it really is.

According to the National Center for Biotechnology Information (NCBI) in a clinical trial, 33% of patients receiving capsaicin cream reported a significant reduction in pruritus compared to only 7% in the placebo group. This illustrates capsaicin’s potential usefulness in treating PN symptoms. Furthermore, the growing interest in natural and over-the-counter medicines is driving up the market for capsaicin cream. The American Academy of Dermatology points out that topical capsaicin is available without a prescription making it a viable alternative for many people.

Will Lack of Qualified Healthcare Professionals Hamper the Prurigo Nodularis Treatment Market?

Okay, so the prurigo nodularis treatment market might face a challengenot enough doctors and nurses who really know how to handle it. But don't worry, there's hope! More and more people are actually getting prurigo nodularis (PN) worldwide, which helps drive the need for more treatment options and experts. We don't have perfect numbers, since it's often missed, but in the US, it's estimated that about 72 out of every 100,000 people have it. Plus, we're getting better at spotting it! A study from 2022 in the Journal of the American Academy of Dermatology showed that using a dermatoscope boosted diagnostic accuracy by 23% compared to just a regular checkup.

This positive economic forecast should encourage more money flowing into new treatments and training for specialists. Plus, remember when the FDA approved dupilumab for Prurigo Nodularis (PN) in 2022? That really got people talking and paying attention to this area. The National Eczema Association says that dupilumab cut itch severity by 60% in studies, which could seriously improve life for people suffering from PN. Sure, we're still worried about not having enough healthcare workers. However, a few things could help make up for that. Even with the staffing issues, the fact that more people know about the disease, there's money to be made, and treatments are getting better should draw more specialists in and help the market grow. Still, figuring out how to get more healthcare staff involved is super important if we want to unlock the market's full potential.

Category-Wise Acumens

Will Widespread Use and Trust in Corticosteroids Influence the Product Segment?

Corticosteroids are really the heavy hitters in treating this condition, mainly because they're so good at calming down inflammation and stopping the itch. Doctors, especially dermatologists, often reach for them first. You can get them as creams and ointments you rub on (topical), pills you swallow (oral), or even shots (injectable). Basically, they work by dialing down the immune system's reaction that's causing all that itchy trouble, bringing much-needed relief. The creams and ointments, or topical corticosteroids, are especially liked because you can put them right where it hurts. This means they target the problem directly, without causing as many body-wide (systemic) side effects that you might get from taking pills or shots. All this widespread use and doctors trusting them, backed by lots of research and years of experience, really cements corticosteroids as the top dog in treating this problem.

Corticosteroids’ dominance in the PN therapy market is driven not only by their efficacy but also by their availability. These drugs are readily available and come in a variety of dosages and formulations making them appropriate for different stages and severity levels of PN. This flexibility enables healthcare providers to adjust treatment strategies to particular patient demands, hence improving treatment outcomes. Furthermore, corticosteroids are frequently covered by insurance programs which reduces patients’ financial burden and encourages treatment adherence.

Will the Rising Preference for Medications Drive Growth in the Distribution Channel Segment?

When it comes to getting medicine for prurigo nodularis, expect retail pharmacies to be the fastest-growing option! That’s because more and more people are choosing to get their prescriptions filled at places like Walgreens and CVS. Why? Well, accessibility and convenience play a huge role. It’s often just easier to pop into your local pharmacy – they usually have longer hours and are right there in your neighborhood, making them way more accessible than trying to get to a hospital or even ordering online. So, for many folks dealing with the really uncomfortable and even debilitating symptoms of prurigo nodularis, a quick trip to the pharmacy for fast relief becomes the obvious, first choice.

Retail pharmacies frequently offer numerous incentives to attract patients such as discounts and loyalty programs. These cost-cutting approaches are especially tempting to patients who need long-term treatment for chronic illnesses such as prurigo nodularis. The economic benefits provided by retail pharmacies can greatly lessen patient’s financial burden encouraging them to continue their therapy uninterrupted. This is especially critical in the treatment of prurigo nodularis where strict adherence to prescribed medication regimens is required for successful symptom control and flare-up avoidance.

Gain Access into Prurigo Nodularis Treatment Market Report Methodology

Country/Region-wise Acumens

Will the Rising Disease Awareness Drive the Growth in the Asia Pacific Region?

The Asia Pacific region? Yeah, it's gearing up for some serious growth in the market for treating Prurigo Nodularis (PN). Think about it – more and more people are actually understanding what PN is, and the healthcare systems are getting better too. It's simpleas folks, patients and doctors alike, recognize PN's symptoms and impact, they're going to be looking for real solutions. And get thisaccording to research in the Journal of the American Academy of Dermatology, PN hits somewhere between 0.1% and 3.8% of the population in Asia, depending on where you are and who you're talking about. Considering how HUGE the populations are in places like China and India, that's a massive potential market for anyone offering PN treatments.

Organizations such as the International Forum for the Study of Itch (IFSI) and the Asian Academy of Dermatology and Venereology (AADV) have played an important role in educating both patients and healthcare professionals about PN contributing to the increase in disease awareness. According to World Health Organization (WHO) research, dermatological disorders including PN are becoming more widely recognized as serious health concerns in the Asia Pacific region with a 15% increase in reported cases in the last five years.

Will the Rising Healthcare Expenditures and a Growing Patient Population Boost the Market in the North American Region?

We're likely to see the North American market for prurigo nodularis (PN) treatments really take off, and here's why. A big reason is that we're spending more and more on healthcare. Consider thisthe Centers for Medicare and Medicaid Services (CMS) say U.S. healthcare spending went past a whopping USD 4.3 Trillion in 2021, a 2.7% jump from the year before! And that upward trend isn't stopping anytime soon – predictions show we'll be hitting USD 6.2 Trillion by 2028. This massive investment in healthcare infrastructure and research is paving the way for new and better PN treatments. Plus, simply put, the number of people needing treatment is growing, and that's definitely fueling market growth.

Another big reason we're seeing more PN is simply that we're getting better at spotting it! Organizations like the National Eczema Association are working hard to raise awareness about PN and similar conditions, which means doctors are recognizing and diagnosing it more often. That, plus improvements in how we diagnose it, should lead to more people being identified, which will help the market grow. We're also seeing a boost from all the research happening. The National Institutes of Health (NIH) is putting money into PN research, and if you look on clinicaltrials.gov, you'll find over 20 clinical trials actively testing or recruiting for PN treatments as of 2024! All these potential new treatments are expected to give us better ways to help patients, which will, in turn, fuel market expansion.

Competitive Landscape

The prurigo nodularis treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the prurigo nodularis treatment market include

  • Bayer AG
  • Galderma SA (Nestle Skin Health Company)
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline Plc
  • VYNE Therapeutics, Inc.
  • Trevi Therapeutics, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson

Latest Developments

  • In February 2023, Pfizer is planning an unprecedented number of pharmaceutical launches with the corporation expected to release 19 new drugs over the next 18 months.
  • In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA-based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed-upon deal is subject to customary closing conditions and is fully consistent with Novartis’ strategy to focus on innovative medicines. It will significantly expand its renal portfolio, complementing the existing pipeline.

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Growth Rate

CAGR of ~5.30% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Product
  • Distribution Channel
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Bayer AG, Galderma SA (Nestle Skin Health Company), Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, VYNE Therapeutics, Inc., Trevi Therapeutics, Inc, Merck & Co., Inc., Novartis AG,Celgene Corporation, Teva Pharmaceutical Industries Ltd., Johnson & Johnson

Customization

Report customization along with purchase available upon request

Prurigo Nodularis Treatment Market, By Category

Product

  • Antihistamines
  • Capsaicin Cream
  • Corticosteroids
  • Emollients
  • Others

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We dig deep into the market, using both qualitative and quantitative analysis, and break it down into segments based on things like economics, but also other important factors. We'll give you the market value (in USD Billion) for every segment and sub-segment. Plus, we'll pinpoint which region and segment we think will grow the fastest and be the biggest overall. You'll get a geography-focused analysis that highlights product/service consumption in each region, explaining what's impacting the market there. We also map out the competitive landscape, showing you the market ranking of the big players, their new product launches, partnerships, business expansions, and acquisitions over the last five years. Expect detailed company profiles too, with overviews, insights, product benchmarking, and SWOT analysis for all the major companies. We cover the present and future market outlook, considering recent happenings like growth opportunities, drivers, and challenges in both new and established regions. We even include an in-depth look at the market through Porter's five forces analysis and a value chain breakdown. Finally, we provide a market dynamics scenario, showing potential growth opportunities in the years ahead, and offer 6-month post-sales analyst support to help you navigate it all.

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Pivotal Questions Answered in the Study

Some of the key players leading in the market include Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co., Inc., Sanofi SA, and GlaxoSmithKline plc.
The primary factor driving the prurigo nodularis treatment market is the increasing prevalence of the condition, coupled with a growing awareness of its impact on quality of life. This drives demand for more effective and targeted therapies. Additionally, advancements in medical research identifying specific molecular pathways involved in the disease are leading to the development of new, targeted treatments.
The prurigo nodularis treatment market is estimated to grow at a CAGR of 5.30% during the forecast period.
<di

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email